Pharmabiz50m
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Pharmabiz1h
iiCON funds 11 new innovative projects focused on tackling infectious diseases
After successful sandpit events in Liverpool and London earlier this year, iiCON (Infection Innovation Consortium) is excited to announce 11 new projects during World AMR Awareness Week. These ...
Pharmabiz2h
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
Pharmabiz3h
Ayush Ministry to amend D&C Rules to regulate retail outlets of ASU drugs
Ayush Ministry to amend D&C Rules to regulate retail outlets of ASU drugs: Peethaambaran Kunnathoor, Chennai Monday, November 18, 2024, 08:00 Hrs [IST] The Union Ministry of Ayush ...
Pharmabiz3h
Nutraceuticals under drug regulation more beneficial; recommendations lack important aspects: Experts
Nutraceuticals under drug regulation more beneficial; recommendations lack important aspects: Experts: Gireesh Babu, New Delhi Monday, November 18, 2024, 08:00 Hrs [IST] Bringing ...
Pharmabiz3h
Pharmaceuticals exports report 8.21 per cent growth in October
Exports of drugs and pharmaceuticals from the country registered a growth of 8.21 per cent during the month of October this year, as compared to the same month of last year. Imports during the month ...
Pharmabiz3h
Indian cancer centres adopting patient-reported outcomes to assess benefit-risk profile of therapies
Indian cancer care centres are now increasingly working to adopt patient-reported outcomes (PRO) to chip in a therapy’s benefit-risk assessment. This follows after a US FDA guidance on Core ...
Pharmabiz1d
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease
Eisai Co., Ltd. and Biogen Inc., a leading biotechnology company, announced a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Pharmabiz1d
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions: Woburn, Massachusetts Saturday, November 16, 2024, 17:00 Hrs ...
Pharmabiz1d
icometrix’s AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment
AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...
Pharmabiz1d
LEO Pharma’s Anzupgo cream to treat chronic hand eczema receives marketing approval in Switzerland
LEO Pharma’s Anzupgo cream to treat chronic hand eczema receives marketing approval in Switzerland: Ballerup, Denmark Saturday, November 16, 2024, 15:00 Hrs [IST] LEO Pharma A/S ...
Pharmabiz1d
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836: Lyon, France Saturday, November 16, 2024, 14:00 Hrs [IST] O ...